spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Oxytrol 

 HSMN NewsFeed - 25 Jan 2013
FDA Approves OXYTROL(R) FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 8 Dec 2011
Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 16 Dec 2010
Watson and Richter Announce Exclusive License Agreement for Esmya
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Aug 2010
Watson Plans Q4 2010 ella(R) (ulipristal acetate) Emergency Contraceptive Launch
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Mar 2010
Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 1 Feb 2010
Watson and HRA Pharma Announce Exclusive Licensing Agreement to Commercialize Novel Emergency Contraceptive in the U.S.
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Dec 2009
New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of Watson's RAPAFLO(R) (silodosin) for Benign Prostatic Hyperplasia (BPH) Symptom Relief
Biopharmaceuticals Urology
 HSMN NewsFeed - 28 Oct 2009
Watson and Barr Settle Lawsuit Over Oxytrol(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 21 May 2009
Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Biopharmaceuticals Urology
 HSMN NewsFeed - 8 May 2009
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Apr 2009
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals Urology
 HSMN NewsFeed - 27 Jan 2009
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 8 Oct 2008
Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals FDA Urology
 HSMN NewsFeed - 21 May 2008
Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Jan 2008
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 12 Dec 2006
Paladin and Auxilium Sign Exclusive Distribution Agreement for Testim'R'
Biopharmaceuticals Distribution
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
Oxytrol
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!